When is follow-up after cancer treatment recommended for lobular carcinoma in situ?

LCIS is a change in breast lobule cells that can signal a higher future risk in either breast; it is not the same as an invasive tumour. Surveillance helps your team compare breast findings over time and decide whether additional assessment is needed. The plan depends on how LCIS was found, biopsy results, family history, breast density, age, and whether surgery or risk-reducing medicine was discussed.

Keep every breast clinic and imaging appointment, and bring reports from outside facilities. Tell your clinician about a new lump, nipple change, skin change, discharge, or persistent focal pain, even if your next appointment is close. Take preventive medicine exactly as prescribed and report troublesome effects before stopping it. Ask which imaging test is planned, who will coordinate your care, and how you will receive results.

Contact your breast team promptly for a new or changing breast lump, bloody or spontaneous nipple discharge, nipple inversion, a persistent skin change, or swelling in the armpit. Seek urgent help for severe illness, sudden breathing difficulty, or chest pain. These symptoms need assessment; they do not by themselves establish cancer.

Which follow-up schedule fits my biopsy and family history? Do I need breast imaging in addition to clinical examinations? What changes should I report between visits? Would a genetics referral or preventive medicine discussion be useful for me?